Statement
Takeda Provides Update on Status of Acquisition of Own Shares(Pursuant to the provision of its Articles of Incorporation in accordance withArticle 459, paragraph 1 of the Companies Act of Japan)
OSAKA, Japan, February 3, 2022 – Takeda Pharmaceutical Company Limited(TSE:4502/NYSE:TAK) (“Takeda”) today provided an update on the status of acquisition of its own
shares which is being carried out pursuant to the provision of its Articles of Incorporation in accordancewith Article 459, paragraph 1 of the Companies Act of Japan, as detailed below.
1.

Class of shares acquired:

Shares of common stock2.

Number of shares acquired:0 shares3.

Acquisition cost of shares acquired:

JPY 0

4.

Period of acquisition:

From January 1, 2022 to January 31, 2022
(execution base)5.

Method of acquisition:

Open-market repurchase through a trust bank(Reference)
1.

Details of the resolution at the Board of Directors’ meeting held on October 28, 2021

(1) Class of shares to be acquired:

Shares of common stock(2) Total number of shares to be acquired:

Up to 35 million shares(equivalent to 2.23% of the total number of sharesoutstanding excluding treasury shares)(3) Total acquisition cost of shares to be acquired: Up to JPY 100 billion(4) Schedule of acquisition:

From November 2, 2021 to April 29, 2022

(5) Method of acquisition:

Open-market repurchase through a trust bank2.

Accumulated company’s own shares acquired through January 31, 2022, pursuant to the above
Board resolution(1) Number of shares acquired:

15,335,700 shares(2) Acquisition cost of shares acquired:

JPY 49,979,942,100

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&Ddriven biopharmaceutical leader headquartered in Japan, committed to discover and deliver lifetransforming treatments, guided by our commitment to patients, our people and the planet. Takeda
focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology,
Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived
Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute tomaking a difference in people’s lives by advancing the frontier of new treatment options and leveraging
our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline.
Our employees are committed to improving quality of life for patients and to working with our partners inhealth care in approximately 80 countries and regions. For more information,
visit https://www.takeda.com.
Media Contacts:
Japanese Media
Ryoko Matsumoto
ryoko.matsumoto@takeda.com+81 (0) 3-3278-2037

Investor Contacts:
Christopher O’Reilly
takeda.ir.contact@takeda.com+81 (0) 3-3278-2306

Important Notice
For the purposes of this notice, “statement” means this document, any oral presentation, any question andanswer session and any written or oral material discussed or distributed by Takeda Pharmaceutical
Company Limited (“Takeda”) regarding this release. This statement (including any oral briefing and anyquestion-and-answer in connection with it) is not intended to, and does not constitute, represent or form
part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for,exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in anyjurisdiction. No shares or other securities are being offered to the public by means of this statement. No
offering of securities shall be made in the United States except pursuant to registration under the U.S.
Securities Act of 1933, as amended, or an exemption therefrom. This statement is being given (togetherwith any further information which may be provided to the recipient) on the condition that it is for use by
the recipient for information purposes only (and not for the evaluation of any investment, acquisition,
disposal or any other transaction). Any failure to comply with these restrictions may constitute a violationof applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In thisstatement, “Takeda” is sometimes used for convenience where references are made to Takeda and its
subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries ingeneral or to those who work for them. These expressions are also used where no useful purpose is servedby identifying the particular company or companies.
The product names appearing in this document are trademarks or registered trademarks owned by Takeda,
or their respective owners.
Forward-Looking Statements
This statement and any materials distributed in connection with this statement may contain forwardlooking statements, beliefs or opinions regarding Takeda’s future business, future position and results ofoperations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forwardlooking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”,

“expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”,“estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements
are based on assumptions about many important factors, including the following, which could cause
actual results to differ materially from those expressed or implied by the forward-looking statements: theeconomic circumstances surrounding Takeda’s global business, including general economic conditions inJapan and the United States; competitive pressures and developments; changes to applicable laws andregulations, including global health care reforms; challenges inherent in new product development,
including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof;
uncertainty of commercial success for new and existing products; manufacturing difficulties or delays;
fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy ofmarketed products or product candidates; the impact of health crises, like the novel coronavirus
pandemic, on Takeda and its customers and suppliers, including foreign governments in countries inwhich Takeda operates, or on other facets of its business; the timing and impact of post-merger
integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s
operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent
Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange
Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or atwww.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained inthis statement or any other forward-looking statements it may make, except as required by law or stock
exchange rule. Past performance is not an indicator of future results and the results or statements of
Takeda in this statement may not be indicative of, and are not an estimate, forecast, guarantee or
projection of Takeda’s future results.
###